Skip navigation
|
Contact Us
[
Viewing Options
]
Search this site
Home
Hepatitis C
The Liver & Hepatitis C
Living with Hepatitis C
Treatment
Wellness
Support
Hepatitis C Trust
News
News
News
2009
2008
December
News From AASLD Liver Conference 2008
AASLD 2008 - Outcomes of Acute Hepatitis C Virus Infection in People with HIV
AASLD 2008 - Genotype 1 HCV Patients with Early but not Rapid Response May Benefit from 72 Week of Pegylated Inte
AASLD 2008 - HCV Protease Inhibitor Telaprevir (VX-950) Continues to Perform Well in PROVE Trials
AASLD 2008 - Intravenous silibinin for treatment of nonresponders to peginterferon/ribavirin therapy in chronic hepatitis C
AASLD 2008 - IDEAL Researchers Look at Predictors of Response to Pegylated Interferon plus Ribavirin including race ethnicity and anemia
AASLD 2008 - HCV Protease Inhibitor Boceprevir plus Pegylated Interferon/Ribavirin Increases Sustained Virological Response Rate: SPRINT-1 Study
AASLD 2008 - Efficacy of Initial Treatment May Predict Long-Term Outcome in Chronic Hepatitis C Patients: Presented at AASLD
AASLD 2008 - HCV Polymerase Inhibitor R7128 Demonstrates Good Antiviral Activity in Genotype 2 or 3 Prior Non-responders and Relapsers
November
October
September
August
July
June
World Hepatitis Day News
May
April
March
February
January
2007
2006
2005
2004
Print this page
Email to a friend
Comment on this page
Link to this page
Add page to favourites
News
>
2008
>
News From AASLD Liver Conference 2008
News From AASLD Liver Conference 2008
Last updated:18November2008
AASLD 2008 - Outcomes of Acute Hepatitis C Virus Infection in People with HIV
AASLD 2008 - Genotype 1 HCV Patients with Early but not Rapid Response May Benefit from 72 Week of Pegylated Inte
AASLD 2008 - HCV Protease Inhibitor Telaprevir (VX-950) Continues to Perform Well in PROVE Trials
AASLD 2008 - Intravenous silibinin for treatment of nonresponders to peginterferon/ribavirin therapy in chronic hepatitis C
AASLD 2008 - IDEAL Researchers Look at Predictors of Response to Pegylated Interferon plus Ribavirin including race ethnicity and anemia
AASLD 2008 - HCV Protease Inhibitor Boceprevir plus Pegylated Interferon/Ribavirin Increases Sustained Virological Response Rate: SPRINT-1 Study
AASLD 2008 - Efficacy of Initial Treatment May Predict Long-Term Outcome in Chronic Hepatitis C Patients: Presented at AASLD
AASLD 2008 - HCV Polymerase Inhibitor R7128 Demonstrates Good Antiviral Activity in Genotype 2 or 3 Prior Non-responders and Relapsers
[
Sign In
]
[
Sign Up
]
